




Count or Los Ansens Public Healt


Key Points from "Penicillin Allergy Delabeling: An Antibiotic Stewardship Initiative"





- 10-20% of the US population reports a penicillin allergy, but >90% are not allergic
- True penicillin-associated anaphylaxis is very rare
- Reasons for inaccurate penicillin allergy labels:
- Mislabeling of adverse effects
- Initial misdiagnosis (viral exanthem)
- Waning sensitivity (every year, ~10% of patients lose their penicillin sensitivity)



		Court of Los Assess Public Health
Case #6 (cont.) Utilization of PEN-FAST	[
Answer: 1 (Treatment required)	PEN Penicillin allergy reported by patient F Five years or less since reaction ¹	 If yes, proceed with assessment 2 points
 Internationally validated clinical decision rule for adult 	A Anaphylaxis or angioedema on S Severe cutaneous adverse reaction th	2 points
 patients Score <3 associated with low 	T Treatment required for reaction ³	1 point Total points
 risk of true penicillin allergy (negative predictive value of 96.3%) Also validated in special populations (pregnancy, emergency department, intensive care unit) 	Interpretation From	









Public Health Case #8 (cont.) Management of Acute Reactions Answer: Oral antihistamine (for presumed allergic angioedema) Adult d • Most reactions consist either <19 kg: 0,1 mg 10-25 kg: 0,15 i 30 mg of subjective symptoms or minor cutaneous reactions 1 to 2 mg/kg/dose (M 25-50 mg Standby medications: 10-20 ma Intramuscular and/or 2 to 5 years: 2.5-Children 28 year intranasal epinephrine Oral antihistamine (2nd 2 to 11 years: 90-300 m generation non-sedating 20-60 mg 2 ma/kg preferred) Inhaled/nebulized bronchodilator H2 blocker


Steroids (oral and/or parenteral)


2.5-5 mg every 20 minutes for








	Court or Los Averus Public Health
Case #8 (cont.)	
Management of Acute React	tions
Severe reactions are extreme	ely rare
 Meta-analysis of 56 studie challenges showed that se 5 of 9225 patients (0.05%) 	evere reactions occurred in only
	Blumenthal KG et a. JAMA Intern Med. 2024 12



















Inappropriate penicillin allergy labels pose a significant public

· Delabeling can be performed by trained nurses, pharmacists,

Direct amoxicillin challenges are safe and effective for low risk

advanced practice providers, and non-allergist physicians





CPublic Health

Countries Los Anders Public Health

References

Summary

patients

health concern

- PMID: 32663245.
 UR, Man JTS, Saloccioli I, Aczarino JIO, Shah RJ, Alvi FL, Cardoso Fernandes A, Ferreira da Silva R, Schumemann HJ, Sousa-Pieto B. Baszcioe Risk T ugar, A Systematic Inview and Meta-Analysis. JAMA Intern Med. 2024 Nov 1;184[1]:1374-1383. doi:10.1001/janaintermed.2024.4666. PMID:

- Biomedia (S., beni K., beni K., beni K., Bolingi K., Lawing K., B., Ball, S., Ball, S.
- on U, Accarino J, Wurcel AG, Jaggers J, Judd A, Blumenthal KG. Penicilin allergy delabeling: Opportunities for imple y Asthma Immunol. 2023 May;130(5):554-564. doi: 10.1016/j.anai.2022.12.023. Epub 2022 Dec 20. PMID: 36563744

Public Health

References

- 12. Staker ML, Walluca DV, Golden DBL, Oppenheimer J, Benntskin JA, Campbell RL, Dinatar C, Elis A, Greenhaut M, Khan DA, Lang Ponton, J, Kami MA, Sakua DW, Wang J, Calibabotatory, Bible N, Boborseniki JAM, Bontzayer J, Doain, J, Forderi A, Finn J, Harsen K, Honer C, Hanni M, Kang J, Calibabotatory, Bible N, Boborseniki JAM, Bontzayer JD, Malana JL, Maphy P, Padoka J, Fine J, Kani JA, Lang MD, Lang J, Calibabotatory, Bible J, Bobraso J, Bortager J, Bontzayer JD, Barbard J, Maghy P, Padoka JA, Finn J, Barbard J, Barbard
- USE (1) June 2011 2021. A MOL DiseAMAP
 Tahanano J, Wang X, Da XY, Booke X, Pu L Douglas A, Shore CA, Yu K, Greenmelly L, Horines NF, Pellipe L Dovelopment and Validational Pancellin Alling Christi Decision Akui Antoni Mai. 2020 May (1) LIMO(2) 47-32. doi:10.1016/j.imutermed.2010001. MMI: 3117048 (MARC: MACONST All March Carl DiseAmap (1) Limo(2) 47-32. doi:10.1016/j.imutermed.2010011. MMI: 3117048 (MARC: MACONST All March Carl DiseAmap (2) Limo(2) 47-32. doi:10.1016/j.imutermed.2010.0116 (Jimutermed.2010011. MMI: 3117048 (MARC: MACONST All March Network (3) Limo(2) 47-40. doi:10.1016/j.imutermed.2010.0116 (Jimutermed.2010011. MMI: 3117048 (Jimutermed.2010011. MMI: 3117048 (Jimutermed.2010011. Jimutermed.2010011. Jimutermed.201011. Jimutermed.2010111. Jimutermed.201011. Jimutermed.2010111. Jimu
- Mich. J. Mich. 202000.
 Mich. 2010 Statement of the statement of